Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Schwaederle

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Journal of the National Cancer Institute|September 18, 2015
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA ApprovalDenis L Jardim, Denis L Fontes Jardim, Maria Schwaederle, et al.
Cancer Research|August 16, 2017
Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation SequencingMaria Schwaederle, Ranajoy Chattopadhyay, Shumei Kato, et al.
Plos One|September 7, 2012
K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivoIrmgard Hofmann, Andreas Weiss, Gaelle Elain, et al.
Molecular Cancer Therapeutics|February 14, 2016
Precision Oncology: The UC San Diego Moores Cancer Center PREDICT ExperienceMaria Schwaederle, Barbara A Parker, Richard B Schwab, et al.
Oncotarget|September 30, 2015
Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncologySandip P Patel, Maria Schwaederle, Gregory A Daniels, et al.
The Oncologist|May 7, 2014
Molecular tumor board: the University of California-San Diego Moores Cancer Center experienceMaria Schwaederle, Barbara A Parker, Richard B Schwab, et al.
Oncotarget|May 10, 2014
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsJennifer J Wheler, Barbara A Parker, Jack J Lee, et al.
Nature Medicine|April 24, 2019
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT studyJason K Sicklick, Shumei Kato, Ryosuke Okamura, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of the National Cancer Institute|September 18, 2015
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA ApprovalDenis L Jardim, Denis L Fontes Jardim, Maria Schwaederle, et al.
Cancer Research|August 16, 2017
Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation SequencingMaria Schwaederle, Ranajoy Chattopadhyay, Shumei Kato, et al.
Plos One|September 7, 2012
K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivoIrmgard Hofmann, Andreas Weiss, Gaelle Elain, et al.
Molecular Cancer Therapeutics|February 14, 2016
Precision Oncology: The UC San Diego Moores Cancer Center PREDICT ExperienceMaria Schwaederle, Barbara A Parker, Richard B Schwab, et al.
Oncotarget|September 30, 2015
Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncologySandip P Patel, Maria Schwaederle, Gregory A Daniels, et al.
The Oncologist|May 7, 2014
Molecular tumor board: the University of California-San Diego Moores Cancer Center experienceMaria Schwaederle, Barbara A Parker, Richard B Schwab, et al.
Oncotarget|May 10, 2014
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsJennifer J Wheler, Barbara A Parker, Jack J Lee, et al.
Nature Medicine|April 24, 2019
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT studyJason K Sicklick, Shumei Kato, Ryosuke Okamura, et al.
Pageof 3